Reinhold Kreutz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4702359/publications.pdf

Version: 2024-02-01

276 papers	21,405 citations	46918 47 h-index	10708 138 g-index
290 all docs	290 docs citations	290 times ranked	25809 citing authors

#	Article	IF	Citations
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	1.0	6,826
2	2018 ESC/ESH Guidelines for the management of arterial hypertension. Journal of Hypertension, 2018, 36, 1953-2041.	0.3	2,129
3	Physiology of Local Renin-Angiotensin Systems. Physiological Reviews, 2006, 86, 747-803.	13.1	1,433
4	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research, 2020, 116, 1666-1687.	1.8	1,074
5	A Prospective Evaluation of an Angiotensin-Convertingâ€"Enzyme Gene Polymorphism and the Risk of Ischemic Heart Disease. New England Journal of Medicine, 1995, 332, 706-712.	13.9	864
6	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension, 2018, 36, 2284-2309.	0.3	689
7	2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. Journal of Hypertension, 2021, 39, 1293-1302.	0.3	349
8	Hypertension, the reninâ€"angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovascular Research, 2020, 116, 1688-1699.	1.8	282
9	2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Pressure, 2018, 27, 314-340.	0.7	254
10	Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radical Biology and Medicine, 2001, 31, 1456-1464.	1.3	244
11	Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease. Nature Genetics, 1996, 13, 429-434.	9.4	237
12	Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematology,the, 2016, 3, e12-e21.	2.2	215
13	Co-expression of renin-angiotensin system genes in human adipose tissue. Journal of Hypertension, 1999, 17, 555-560.	0.3	201
14	Extracellular Signal-regulated Kinase Plays an Essential Role in Hypertrophic Agonists, Endothelin-1 and Phenylephrine-induced Cardiomyocyte Hypertrophy. Journal of Biological Chemistry, 2000, 275, 37895-37901.	1.6	166
15	Management consensus guidance for the use of rivaroxaban â€" an oral, direct factor Xa inhibitor. Thrombosis and Haemostasis, 2012, 108, 876-886.	1.8	155
16	Association Between the Angiotensinogen 235T-Variant and Essential Hypertension in Whites. Hypertension, 1997, 30, 1331-1337.	1.3	155
17	A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. European Heart Journal, 2014, 35, 1069-1077.	1.0	137
18	Angiotensin-Converting Enzyme I/D Polymorphism and Arterial Wall Thickness in a General Population. Circulation, 1995, 91, 2721-2724.	1.6	117

#	Article	IF	Citations
19	Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundamental and Clinical Pharmacology, 2012, 26, 27-32.	1.0	97
20	Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. Journal of the American College of Cardiology, 2003, 41, 666-673.	1.2	94
21	Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. American Journal of Medicine, 2019, 132, 1078-1083.	0.6	93
22	Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin???angiotensin-system gene expression and cardiovascular functions. Journal of Hypertension, 1995, 13, 891-899.	0.3	91
23	Modeled gravitational unloading induced downregulation of endothelin-1 in human endothelial cells. Journal of Cellular Biochemistry, 2007, 101, 1439-1455.	1.2	88
24	European Society of Hypertension position paper on renal denervation 2021. Journal of Hypertension, 2021, 39, 1733-1741.	0.3	88
25	Simulated weightlessness changes the cytoskeleton and extracellular matrix proteins in papillary thyroid carcinoma cells. Cell and Tissue Research, 2006, 324, 267-277.	1.5	87
26	Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study. CKJ: Clinical Kidney Journal, 2019, 12, 663-672.	1.4	82
27	Anticontractile Effect of Perivascular Adipose Tissue and Leptin are Reduced in Hypertension. Frontiers in Pharmacology, 2012, 3, 103.	1.6	78
28	Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes and Endocrinology,the, 2016, 4, 507-516.	5.5	78
29	A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thrombosis and Haemostasis, 2014, 111, 94-102.	1.8	74
30	Increased Transient Receptor Potential Channel TRPC3 Expression in Spontaneously Hypertensive Rats. American Journal of Hypertension, 2005, 18, 1503-1507.	1.0	68
31	Salt Susceptibility Maps to Chromosomes 1 and 17 With Sex Specificity in the Sabra Rat Model of Hypertension. Hypertension, 1998, 31, 119-124.	1.3	64
32	Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Caseâ€“Control Surveillance Study. European Journal of Clinical Pharmacology, 2015, 71, 219-227.	0.8	63
33	Congenic Substitution Mapping Excludes Sa as a Candidate Gene Locus for a Blood Pressure Quantitative Trait Locus on Rat Chromosome 1. Hypertension, 1999, 34, 643-648.	1.3	62
34	Genetic Dissection of Increased Urinary Albumin Excretion in the Munich Wistar FrÃ¶mter Rat. Journal of the American Society of Nephrology: JASN, 2002, 13, 2706-2714.	3.0	62
35	Drugâ€induced liver injury: results from the hospitalâ€based <scp>B</scp>erlin Caseâ€“Control Surveillance Study. British Journal of Clinical Pharmacology, 2015, 79, 988-999.	1.1	62
36	Effect of high NaCl diet on spontaneous hypertension in a genetic rat model with reduced nephron number. Journal of Hypertension, 2000, 18, 777-782.	0.3	61

#	Article	IF	Citations
37	Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Frontiers in Pharmacology, 2018, 9, 1131.	1.6	61
38	Hypertension, a Moving Target in COVID-19. Circulation Research, 2021, 128, 1062-1079.	2.0	61
39	A Major Gene Locus Links Early Onset Albuminuria with Renal Interstitial Fibrosis in the MWF Rat with Polygenetic Albuminuria. Journal of the American Society of Nephrology: JASN, 2003, 14, 3081-3089.	3.0	58
40	The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics and Genomics, 2004, 14, 665-671.	5.7	57
41	Effects of basic fibroblast growth factor on endothelial cells under conditions of simulated microgravity. Journal of Cellular Biochemistry, 2008, 104, 1324-1341.	1.2	57
42	Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study. European Heart Journal, 2019, 40, 2021-2028.	1.0	54
43	Selective Loss of Podoplanin Protein Expression Accompanies Proteinuria and Precedes Alterations in Podocyte Morphology in a Spontaneous Proteinuric Rat Model. American Journal of Pathology, 2008, 173, 315-326.	1.9	53
44	Early onset of chondroitin sulfate and osteopontin expression in angiotensin ii-dependent left ventricular hypertrophy1. American Journal of Hypertension, 2002, 15, 644-652.	1.0	52
45	Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension, 2022, 79, 12-23.	1.3	51
46	Role of matrix metalloproteinase-9Âin chronic kidney disease: a new biomarker of resistant albuminuria. Clinical Science, 2016, 130, 525-538.	1.8	48
47	Development, genotype and phenotype of a new colony of the Sabra hypertension prone (SBH/y) and resistant (SBN/y) rat model of salt sensitivity and resistance. Journal of Hypertension, 1996, 14, 1175-1182.	0.3	47
48	A Gene-Based Genetic Linkage and Comparative Map of the Rat X Chromosome. Genomics, 1997, 40, 253-261.	1.3	47
49	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1522-1545.	0.3	47
50	Renal Endothelin ET _A /ET _B Receptor Imbalance Differentiates Salt-Sensitive From Salt-Resistant Spontaneous Hypertension. Hypertension, 2001, 37, 275-280.	1.3	46
51	Drug-induced agranulocytosis in the Berlin caseâ€“control surveillance study. European Journal of Clinical Pharmacology, 2014, 70, 339-345.	0.8	46
52	Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. Journal of Hypertension, 2019, 37, 1950-1958.	0.3	46
53	Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats. British Journal of Pharmacology, 2000, 130, 205-208.	2.7	45
54	Increase of fibronectin and osteopontin in porcine hearts following ischemia and reperfusion. Journal of Molecular Medicine, 2005, 83, 626-637.	1.7	45

#	Article	IF	Citations
55	Physical Activity in Nursing Homesâ€"Barriers and Facilitators: A Cross-Sectional Study. Journal of Aging and Physical Activity, 2012, 20, 421-441.	0.5	45
56	Expression and Response to Angiotensin-Converting Enzyme Inhibition of Matrix Metalloproteinases 2 and 9 in Renal Glomerular Damage in Young Transgenic Rats with Renin-Dependent Hypertension. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 8-16.	1.3	44
57	Lack of Association Between the MEF2A Gene and Myocardial Infarction. Circulation, 2008, 117, 185-191.	1.6	44
58	Metformin modulates apoptosis and cell signaling of human podocytes under high glucose conditions. Journal of Nephrology, 2016, 29, 765-773.	0.9	44
59	Fixed-dose combination antihypertensive medications. Lancet, The, 2019, 394, 637-638.	6.3	44
60	Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic. Journal of Hypertension, 2021, 39, 1077-1089.	0.3	44
61	Pharmacokinetics and Pharmacodynamics of Rivaroxaban â€“ An Oral, Direct Factor Xa Inhibitor. Current Clinical Pharmacology, 2014, 9, 75-83.	0.2	44
62	Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenetics and Genomics, 2011, 21, 179-184.	0.7	43
63	Nutraceuticals and blood pressure control: a European Society of Hypertension position document. Journal of Hypertension, 2020, 38, 799-812.	0.3	43
64	Cardiac Endothelin System Impairs Left Ventricular Function in Renin-Dependent Hypertension via Decreased Sarcoplasmic Reticulum Ca ²⁺ Uptake. Circulation, 2000, 102, 1582-1588.	1.6	42
65	Role of the Î±-, Î²-, and Î³-Subunits of Epithelial Sodium Channel in a Model of Polygenic Hypertension. Hypertension, 1997, 29, 131-136.	1.3	42
66	Expression of vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia/reperfusion injury. Cardiovascular Pathology, 2007, 16, 291-299.	0.7	40
67	The Trp64Arg polymorphism of the Â3-adrenergic receptor gene is associated with hypertension in men with type 2 diabetes mellitus. American Journal of Hypertension, 2000, 13, 1027-1031.	1.0	39
68	Role of Chromosome X in the Sabra Rat Model of Salt-Sensitive Hypertension. Hypertension, 1999, 33, 261-265.	1.3	38
69	Congenic strains confirm the presence of salt-sensitivity QTLs on chromosome 1 in the Sabra rat model of hypertension. Physiological Genomics, 2003, 12, 85-95.	1.0	38
70	Impaired coronary endothelial function in a rat model of spontaneous albuminuria. Kidney International, 2002, 62, 181-191.	2.6	37
71	Physician attitudes to blood pressure control. Journal of Hypertension, 2011, 29, 1633-1640.	0.3	37
72	Rivaroxabanâ€™s Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961986853.	0.7	37

#	Article	IF	Citations
73	Endothelin-A Receptor Blockade Prevents Left Ventricular Hypertrophy and Dysfunction in Salt-Sensitive Experimental Hypertension. Circulation, 2002, 106, 2305-2308.	1.6	36
74	Genetic linkage of albuminuria and renal injury in Dahl salt-sensitive rats on a high-salt diet: comparison with spontaneously hypertensive rats. Physiological Genomics, 2004, 18, 218-225.	1.0	36
75	Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. Journal of Hypertension, 2020, 38, 1016-1028.	0.3	36
76	Interaction between blood pressure quantitative trait loci in rats in which trait variation at chromosome 1 is conditional upon a specific allele at chromosome 10. Human Molecular Genetics, 2003, 12, 435-439.	1.4	35
77	Genetic kininogen deficiency contributes to aortic aneurysm formation but not to atherosclerosis. Physiological Genomics, 2004, 19, 41-49.	1.0	35
78	Early onset albuminuria in Dahl rats is a polygenetic trait that is independent from salt loading. Physiological Genomics, 2003, 14, 209-216.	1.0	33
79	Mapping genetic determinants of kidney damage in rat models. Hypertension Research, 2012, 35, 675-694.	1.5	33
80	Herb-Induced Liver Injury in the Berlin Case-Control Surveillance Study. International Journal of Molecular Sciences, 2016, 17, 114.	1.8	33
81	Aptamer BC007 for neutralization of pathogenic autoantibodies directed against G-protein coupled receptors: A vision of future treatment of patients with cardiomyopathies and positivity for those autoantibodies. Atherosclerosis, 2016, 244, 44-47.	0.4	33
82	Development of Overt Proteinuria in the Munich Wistar FrÃ¶mter Rat Is Suppressed by Replacement of Chromosome 6 in a Consomic Rat Strain. Journal of the American Society of Nephrology: JASN, 2007, 18, 113-121.	3.0	32
83	Predictive value of venous thromboembolism (<scp>VTE</scp>)â€<scp>BLEED</scp> to predict major bleeding and other adverse events in a practiceâ€based cohort of patients with <scp>VTE</scp>: results of the <scp>XALIA</scp> study. British Journal of Haematology, 2018, 183, 457-465.	1.2	32
84	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. Nephrology Dialysis Transplantation, 2023, 38, 10-25.	0.4	30
85	High Prevalence of Multimorbidity and Polypharmacy in Elderly Patients With Chronic Pain Receiving Home Care are Associated With Multiple Medication-Related Problems. Frontiers in Pharmacology, 2021, 12, 686990.	1.6	30
86	Hpa II polymorphism of the atrial natriuretic peptide gene and the blood pressure response to salt intake in normotensive men. Journal of Hypertension, 1997, 15, 715-718.	0.3	29
87	The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenetics and Genomics, 2005, 15, 831-837.	0.7	29
88	Monocytes From Spontaneously Hypertensive Rats Show Increased Store-Operated and Second Messenger-Operated Calcium Influx Mediated by Transient Receptor Potential Canonical Type 3 Channels. American Journal of Hypertension, 2007, 20, 1111-1118.	1.0	29
89	Nephron deficit is not required for progressive proteinuria development in the Munich Wistar FrÃ¶mter rat. Physiological Genomics, 2008, 35, 30-35.	1.0	29
90	Finerenone Reduces Intrinsic Arterial Stiffness in Munich Wistar FrÃ¶mter Rats, a Genetic Model of Chronic Kidney Disease. American Journal of Nephrology, 2020, 51, 294-303.	1.4	29

#	Article	IF	Citations
91	The First Aptamer-Apheresis Column Specifically for Clearing Blood of Î²1-Receptor Autoantibodies. Circulation Journal, 2012, 76, 2449-2455.	0.7	28
92	Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective. Hypertension, 2021, 78, 555-558.	1.3	28
93	Genetic Loci Contribute to the Progression of Vascular and Cardiac Hypertrophy in Salt-Sensitive Spontaneous Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1211-1217.	1.1	27
94	Olmesartan/amlodipine: a review of its use in the management of hypertension. Vascular Health and Risk Management, 2011, 7, 183.	1.0	27
95	Flupirtine-induced liver injuryâ€"Seven cases from the Berlin Caseâ€"control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database. European Journal of Clinical Pharmacology, 2014, 70, 453-459.	0.8	27
96	XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. Thrombosis Journal, 2014, 12, 16.	0.9	27
97	Evidence for Primary Genetic Determination of Heart Rate Regulation. Circulation, 1997, 96, 1078-1081.	1.6	27
98	Regulation of podoplanin expression by microRNA-29b associates with its antiapoptotic effect in angiotensin II-induced injury of human podocytes. Journal of Hypertension, 2016, 34, 323-331.	0.3	26
99	Role of the Endothelin-1 Gene Locus for Renal Impairment in the General Nondiabetic Population. Journal of the American Society of Nephrology: JASN, 2003, 14, 2596-2602.	3.0	25
100	A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. Journal of Thrombosis and Thrombolysis, 2014, 38, 137-149.	1.0	25
101	ARB-Based Single-Pill Platform to Guide a Practical Therapeutic Approach to Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 137-47.	1.0	25
102	Update of the position paper on arterial hypertension and erectile dysfunction. Journal of Hypertension, 2020, 38, 1220-1234.	0.3	25
103	Analysis of the genomic architecture of a complex trait locus in hypertensive rat models links Tmem63c to kidney damage. ELife, 2019, 8, .	2.8	25
104	CYP3A5 Genotype-Phenotype Analysis in the Human Kidney Reveals a Strong Site-Specific Expression of CYP3A5 in the Proximal Tubule in Carriers of the CYP3A5*1 Allele. Drug Metabolism and Disposition, 2012, 40, 639-641.	1.7	24
105	Towards new recommendations to reduce the burden of alcohol-induced hypertension in the European Union. BMC Medicine, 2017, 15, 173.	2.3	24
106	The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. International Journal of Cardiology, 2018, 253, 71-77.	0.8	24
107	Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer. Breast Cancer Research and Treatment, 2013, 139, 553-560.	1.1	23
108	Nonpharmacologic Pain Management Interventions in German Nursing Homes: A Cluster Randomized Trial. Pain Management Nursing, 2015, 16, 464-474.	0.4	23

#	Article	IF	Citations
109	Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: is dosing in the evening better than in the morning?. Journal of Hypertension, 2020, 38, 1396-1406.	0.3	23
110	The Y Chromosome. Hypertension, 1996, 28, 895-897.	1.3	23
111	Sodium–glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. Journal of Hypertension, 2021, 39, 1090-1097.	0.3	22
112	Do Î²-Blockers Cause Depression?. Hypertension, 2021, 77, 1539-1548.	1.3	22
113	2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action. Journal of Human Hypertension, 2023, 37, 428-437.	1.0	22
114	Neutralization of pathogenic beta1-receptor autoantibodies by aptamers in vivo: the first successful proof of principle in spontaneously hypertensive rats. Molecular and Cellular Biochemistry, 2014, 393, 177-180.	1.4	21
115	Prescribing of inappropriate medication in nursing home residents in Germany according to a French consensus list: a crossâ€sectional cohort study. Pharmacoepidemiology and Drug Safety, 2011, 20, 12-19.	0.9	20
116	Elimination of Severe Albuminuria in Aging Hypertensive Rats by Exchange of 2 Chromosomes in Double-Consomic Rats. Hypertension, 2011, 58, 219-224.	1.3	20
117	Ophthalmic Drugs as Part of Polypharmacy in Nursing Home Residents with Glaucoma. Drugs and Aging, 2013, 30, 31-38.	1.3	20
118	Dissecting the genetic predisposition to albuminuria and endothelial dysfunction in a genetic rat model. Journal of Hypertension, 2013, 31, 2203-2212.	0.3	20
119	Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA. TH Open, 2019, 03, e85-e93.	0.7	20
120	Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 207-216.	1.0	20
121	Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension, 2022, 79, 1153-1166.	1.3	20
122	Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension. Journal of Hypertension, 2003, 21, 2389-2397.	0.3	19
123	Blood Pressure and Arterial Stiffness in Association With Aircraft Noise Exposure:Long-Term Observation and Potential Effect of COVID-19 Lockdown. Hypertension, 2022, 79, 325-334.	1.3	19
124	Pharmacokinetics of Olmesartan Medoxomil plus Hydrochlorothiazide Combination in Healthy Subjects. Clinical Drug Investigation, 2006, 26, 29-34.	1.1	18
125	Profiling of the renal kinome: a novel tool to identify protein kinases involved in angiotensin II-dependent hypertensive renal damage. American Journal of Physiology - Renal Physiology, 2007, 293, F428-F437.	1.3	18
126	Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Expert Opinion on Pharmacotherapy, 2011, 12, 2771-2779.	0.9	18

#	Article	IF	Citations
127	Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome. Thrombosis and Haemostasis, 2014, 112, 419-420.	1.8	18
128	Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical Practice. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 138-146.	0.7	18
129	Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE. TH Open, 2017, 01, e33-e42.	0.7	18
130	Sulfasalazineâ€Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus. Clinical Pharmacology and Therapeutics, 2018, 103, 843-853.	2.3	18
131	Congenic rat strains are important tools for the genetic dissection of essential hypertension. Seminars in Nephrology, 2002, 22, 135-147.	0.6	18
132	Genetic analysis of salt-sensitive hypertension in Dahl rats reveals a link between cardiac fibrosis and high cholesterol. Cardiovascular Research, 2008, 81, 618-626.	1.8	17
133	Renal ACE2 expression and activity is unaltered during established hypertension in adult SHRSP and TGR(mREN2)27. Hypertension Research, 2010, 33, 123-128.	1.5	17
134	Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vascular Health and Risk Management, 2012, 8, 363.	1.0	17
135	Ramipril-Induced Liver Injury: Case Report and Review of the Literature. American Journal of Hypertension, 2013, 26, 1070-1075.	1.0	17
136	Estimating kidney function and use of oral antidiabetic drugs in elderly. Fundamental and Clinical Pharmacology, 2015, 29, 321-328.	1.0	17
137	Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: coâ€medication interactions. British Journal of Clinical Pharmacology, 2016, 81, 724-734.	1.1	17
138	XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America. Thrombosis Research, 2019, 176, 125-132.	0.8	17
139	Small molecules as therapy for uveitis: a selected perspective of new and developing agents. Expert Opinion on Pharmacotherapy, 2017, 18, 1311-1323.	0.9	16
140	Effects of angiotensin II subtype 1 receptor blockade on cardiac fibrosis and sarcoplasmic reticulum Ca2+ handling in hypertensive transgenic rats overexpressing the Ren2 gene. Journal of Hypertension, 2001, 19, 1465-1472.	0.3	15
141	Nephroprotective effects of the endothelin ETA receptor antagonist darusentan in salt-sensitive genetic hypertension. European Journal of Pharmacology, 2003, 468, 209-216.	1.7	15
142	Low-dose lithium combined with captopril prevents stroke and improves survival in salt-loaded, stroke-prone spontaneously hypertensive rats. Journal of Hypertension, 2005, 23, 2277-2285.	0.3	15
143	Genetic low nephron number hypertension is associated with dysregulation of the hepatic and renal insulin-like growth factor system during nephrogenesis. Journal of Hypertension, 2006, 24, 1857-1864.	0.3	15
144	Role of the H1 haplotype of microtubule-associated protein tau (MAPT) gene in Greek patients with Parkinson's disease. BMC Neurology, 2009, 9, 26.	0.8	15

#	Article	IF	Citations
145	Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. Fundamental and Clinical Pharmacology, 2009, 23, 767-774.	1.0	15
146	Improving long-term adherence to statin therapy: a qualitative study of GPsâ€™ experiences in primary care. British Journal of General Practice, 2018, 68, e401-e407.	0.7	15
147	Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. European Heart Journal Supplements, 2020, 22, O78-O86.	0.0	15
148	Membrane microviscosity does not correlate with blood pressure: a cosegregation study. Journal of Hypertension, 1993, 11, 25-30.	0.3	14
149	High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene. Journal of Hypertension, 2007, 25, 1627-1632.	0.3	14
150	Protective effect of female gender on the development of albuminuria in a polygenetic rat model is enhanced further by replacement of a major autosomal QTL. Clinical Science, 2008, 114, 305-311.	1.8	14
151	Short-term treatment with a beta-blocker with vasodilative capacities improves intrarenal endothelial function in experimental renal failure. Life Sciences, 2009, 85, 431-437.	2.0	14
152	Genetics of melatonin receptor type 2 is associated with left ventricular function in hypertensive patients treated according to guidelines. European Journal of Internal Medicine, 2013, 24, 650-655.	1.0	14
153	Are physicians underestimating the challenges of hypertension management? Results from the Supporting Hypertension Awareness and Research Europe-wide (SHARE) survey. European Journal of Preventive Cardiology, 2013, 20, 786-792.	0.8	14
154	Pain management intervention targeting nursing staff and general practitioners: Pain intensity, consequences and clinical relevance for nursing home residents. Geriatrics and Gerontology International, 2017, 17, 1534-1543.	0.7	14
155	Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 463-472.	1.0	14
156	Statin intolerance â€“ a question of definition. Expert Opinion on Drug Safety, 2017, 16, 55-63.	1.0	14
157	Glomerular C4d deposition can precede the development of focal segmental glomerulosclerosis. Kidney International, 2019, 96, 738-749.	2.6	14
158	Deficits in pain medication in older adults with chronic pain receiving home care: A cross-sectional study in Germany. PLoS ONE, 2020, 15, e0229229.	1.1	14
159	Drug-induced kidney injury: A large case series from the Berlin Case-Control Surveillance Study. Clinical Nephrology, 2018, 89, 18-26.	0.4	14
160	Effect of Losartan on Right Ventricular Hypertrophy and Cardiac Angiotensin I-Converting Enzyme Activity in Pulmonary Hypertensive Rats. Clinical and Experimental Hypertension, 1996, 18, 101-111.	0.5	13
161	Pharmacogenetics of antihypertensive drug response. Current Hypertension Reports, 2004, 6, 15-20.	1.5	13
162	Validation of a Modified German Version of the Brief Pain Inventory for Use in Nursing Home Residents with Chronic Pain. Journal of Pain, 2016, 17, 248-256.	0.7	13

#	Article	IF	Citations
163	Hypertension healthcare professional beliefs and behaviour regarding patient medication adherence: a survey conducted among European Society of Hypertension Centres of Excellence. Blood Pressure, 2021, 30, 282-290.	0.7	13
164	No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy. Clinical Science, 2006, 111, 365-372.	1.8	12
165	Quality of life in hypertension management using olmesartan in primary care. Expert Opinion on Pharmacotherapy, 2008, 9, 1641-1653.	0.9	12
166	Genetic variants implicated in telomere length associated with left ventricular function in patients with hypertension and cardiac organ damage. Journal of Molecular Medicine, 2012, 90, 1059-1067.	1.7	12
167	Uromodulin associates with cardiorenal function in patients with hypertension and cardiovascular disease. Journal of Hypertension, 2017, 35, 2053-2058.	0.3	12
168	Cpxm2 as a novel candidate for cardiac hypertrophy and failure in hypertension. Hypertension Research, 2022, 45, 292-307.	1.5	12
169	Rat chromosome 19 transfer from SHR ameliorates hypertension, salt-sensitivity, cardiovascular and renal organ damage in salt-sensitive Dahl rats. Journal of Hypertension, 2007, 25, 95-102.	0.3	11
170	Induction of C1q expression in glomerular endothelium in a rat model with arterial hypertension and albuminuria. Journal of Hypertension, 2007, 25, 2308-2316.	0.3	11
171	Genetic locus on MWF rat chromosome 6 affects kidney damage in response to<scp>l</scp>-NAME treatment in spontaneously hypertensive rats. Physiological Genomics, 2010, 42, 126-133.	1.0	11
172	Treatment Thresholds and Targets in Hypertension. Hypertension, 2018, 71, 966-968.	1.3	11
173	Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Nonâ€“Vitamin K Antagonist Oral Anticoagulants. Mayo Clinic Proceedings, 2018, 93, 1503-1519.	1.4	11
174	Implementing the Proclamation of Stroke and Potentially Preventable Dementias. International Journal of Stroke, 2018, 13, 780-786.	2.9	11
175	Increased dynamin expression precedes proteinuria in glomerular disease. Journal of Pathology, 2019, 247, 177-185.	2.1	11
176	Altered Angiotensinogen Amino Acid Sequence and Plasma Angiotensin II Levels in Genetically Hypertensive Rats. Hypertension, 1995, 26, 279-284.	1.3	11
177	Methodological Aspects of Meta-Analyses Assessing the Effect of Blood Pressureâ€“Lowering Treatment on Clinical Outcomes. Hypertension, 2022, 79, 491-504.	1.3	11
178	Do recent meta-analyses truly prove that treatment with blood pressure-lowering drugs is beneficial at any blood pressure value, no matter how low? A critical review. Journal of Hypertension, 2022, 40, 839-846.	0.3	11
179	Covid-19 associated reduction in hypertension-related diagnostic and therapeutic procedures in Excellence Centers of the European Society of Hypertension. Blood Pressure, 2022, 31, 71-79.	0.7	11
180	The G-231A Polymorphism in the Endothelin-A Receptor Gene Is Associated With Lower Aortic Pressure in Patients With Dilated Cardiomyopathy. American Journal of Hypertension, 2007, 20, 32-37.	1.0	10

#	Article	IF	Citations
181	Tissue Expression of TRPC3 and TRPC6 in Hypertensive Munich Wistar FrÃ¶mter Rats Showing Proteinuria. American Journal of Nephrology, 2010, 31, 36-44.	1.4	10
182	MWF rats with spontaneous albuminuria inherit a reduced efficiency of nephron induction during early nephrogenesis in comparison to SHR rats. Journal of Hypertension, 2012, 30, 2031-2038.	0.3	10
183	Perceived enactment of autonomy of nursing home residents: A ‹scp›G‹/scp›erman crossâ€sectional study. Australian Journal of Cancer Nursing, 2013, 15, 186-193.	0.8	10
184	Targeted resequencing of a locus for heparin-induced thrombocytopenia on chromosome 5 identified in a genome-wide association study. Journal of Molecular Medicine, 2018, 96, 765-775.	1.7	10
185	Importance of in vitro conditions for modeling the in vivo dose in humans by in vitroâ€“in vivo extrapolation (IVIVE). Archives of Toxicology, 2019, 93, 615-621.	1.9	10
186	Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIAâ€LEA noninterventional studies. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 426-438.	1.0	10
187	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace, 2021, 23, 1873-1891.	0.7	10
188	Improving the Management of Hypertension by Tackling Awareness, Adherence, and Clinical Inertia: A Symposium Report. American Journal of Cardiovascular Drugs, 2022, 22, 251-261.	1.0	10
189	Impact of Nephron Number Dosing on Cardiorenal Damage and Effects of ACE Inhibition. American Journal of Hypertension, 2011, 24, 474-481.	1.0	9
190	A Single Nucleotide Polymorphism near the CYP17A1 Gene Is Associated with Left Ventricular Mass in Hypertensive Patients under Pharmacotherapy. International Journal of Molecular Sciences, 2015, 16, 17456-17468.	1.8	9
191	The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study. Vascular Health and Risk Management, 2016, 12, 209.	1.0	9
192	Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. Thrombosis Research, 2017, 155, 23-27.	0.8	9
193	Starting Antihypertensive Drug Treatment With Combination Therapy. Hypertension, 2021, 77, 800-805.	1.3	9
194	Matrix analysis for the dissection of interactions of G-Protein Î²3 subunit C825T genotype, allograft function, and posttransplant hypertension in kidney transplantation. American Journal of Kidney Diseases, 2002, 40, 1319-1324.	2.1	8
195	Decreased cardiac SERCA2 expression, SR Ca uptake, and contractile function in hypothyroidism are attenuated in SERCA2 overexpressing transgenic rats. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H943-H950.	1.5	8
196	Donor Genotype and Intragraft Expression of CYP3A5 Reflect the Response to Steroid Treatment During Acute Renal Allograft Rejection. Transplantation, 2017, 101, 2017-2025.	0.5	8
197	Moderation of alcohol consumption as a recommendation in European hypertension management guidelines: a survey on awareness, screening and implementation among European physicians. BMJ Open, 2018, 8, e022026.	0.8	8
198	Pain, Fear of Falling, and Functional Performance Among Nursing Home Residents: A Longitudinal Study. Western Journal of Nursing Research, 2019, 41, 191-216.	0.6	8

#	Article	IF	Citations
199	A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension. Journal of Hypertension, 2020, 38, 1890-1898.	0.3	8
200	Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors. Frontiers in Psychiatry, 2022, 13, 826138.	1.3	8
201	Differential Development of Early Hypertension in Heterozygous Transgenic TGR(mREN2)27 Rats. Clinical and Experimental Hypertension, 1998, 20, 273-282.	0.5	7
202	An Expectation-Maximizationâ€“Likelihood-Ratio Test for Handling Missing Data. Genetics, 2005, 169, 1021-1031.	1.2	7
203	Pharmacokinetics and Safety of Olmesartan Medoxomil in Combination with Glibenclamide in Healthy Volunteers. Clinical and Experimental Hypertension, 2006, 28, 631-643.	0.5	7
204	Left-Ventricular Structure and Function Are Influenced by Angiotensinogen Gene Polymorphism (â˜20) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.0	7
205	Role of the angiotensin II type 2 receptor gene (+1675G/A) polymorphism on left ventricular hypertrophy and geometry in treated hypertensive patients. Journal of Hypertension, 2010, 28, 1221-1229.	0.3	7
206	Microangiopathy and visual deficits characterize the retinopathy of a spontaneously hypertensive rat model with type 2 diabetes and metabolic syndrome. Hypertension Research, 2011, 34, 103-112.	1.5	7
207	Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients. Expert Opinion on Drug Safety, 2011, 10, 185-196.	1.0	7
208	Induction of albuminuria and kidney damage in SHR by transfer of chromosome 8 from Munich Wistar FrÃ¶mter rats. Physiological Genomics, 2012, 44, 110-116.	1.0	7
209	Efficacy and Tolerability of Tripleâ€Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: A Subgroup Analysis of Patients Stratified by Hypertension Severity, Age, Sex, and Obesity. Journal of Clinical Hypertension, 2014, 16, 729-740.	1.0	7
210	The impact of Î±-Lipoic acid on cell viability and expression of nephrin and ZNF580 in normal human podocytes. European Journal of Pharmacology, 2017, 810, 1-8.	1.7	7
211	Implementing the proclamation of stroke and potentially preventable dementias. Journal of Clinical Hypertension, 2018, 20, 1354-1359.	1.0	7
212	Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study. Current Vascular Pharmacology, 2018, 16, 197-203.	0.8	7
213	Molecular Genetics of Hypertension. Clinical and Experimental Hypertension, 1992, 14, 15-34.	0.3	6
214	Role of CYP2C9 genetic variants for salt sensitivity and the regulation of the reninâ€“angiotensinâ€“aldosterone system in normotensive men. Journal of Hypertension, 2011, 29, 56-61.	0.3	6
215	Tmem63c is a potential pro-survival factor in angiotensin II-treated human podocytes. Life Sciences, 2020, 258, 118175.	2.0	6
216	Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations. Genes, 2020, 11, 1275.	1.0	6

#	Article	IF	Citations
217	Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitroâ€“in vivo extrapolation. Archives of Toxicology, 2021, 95, 1433-1442.	1.9	6
218	Concerted EP2 and EP4 Receptor Signaling Stimulates Autocrine Prostaglandin E2 Activation in Human Podocytes. Cells, 2020, 9, 1256.	1.8	6
219	Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis. TH Open, 2018, 02, e139-e146.	0.7	5
220	Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease. International Journal of Cardiology, 2019, 282, 47-52.	0.8	5
221	Impaired Function of Endothelial Pressure-Activated Cation Channel in Salt-Sensitive Genetic Hypertension. Journal of the American Society of Nephrology: JASN, 2001, 12, 1624-1629.	3.0	5
222	Dissociation of Renin and Aldosterone During Low-Dose Epinephrine Infusion. American Journal of Hypertension, 1994, 7, 913-918.	1.0	4
223	A Twofold Genetic Increase of ACE Expression Has No Effect on the Development of Spontaneous Hypertension. American Journal of Hypertension, 2008, 21, 200-205.	1.0	4
224	Genetic predisposition for glomerulonephritis-induced glomerulosclerosis in rats is linked to chromosome 1. Physiological Genomics, 2008, 35, 173-181.	1.0	4
225	Cardiorenal protection in experimental hypertension with renal failure: comparison between vasopeptidase inhibition and angiotensin receptor blockade. Clinical and Experimental Hypertension, 2015, 37, 26-32.	0.5	4
226	Physician Contacts and Their Influence on the Appropriateness of Pain Medication in Nursing Home Residents: A Cross-Sectional Study. Journal of the American Medical Directors Association, 2016, 17, 834-838.	1.2	4
227	Atrial fibrillation and medication treatment among centenarians: Are all very old patients treated the same?. Geriatrics and Gerontology International, 2018, 18, 1634-1640.	0.7	4
228	Lower Prescription Rates in Centenarians with Heart Failure and Heart Failure and Kidney Disease Combined: Findings from a Longitudinal Cohort Study of Very Old Patients. Drugs and Aging, 2018, 35, 907-916.	1.3	4
229	High-Throughput Sequencing to Investigate Associations Between HLA Genes and Metamizole-Induced Agranulocytosis. Frontiers in Genetics, 2020, 11, 951.	1.1	4
230	Sex Differences in Characteristics Associated with Potentially Inappropriate Medication Use and Associations with Functional Capacity in Older Participants of the Berlin Aging Study II. Gerontology, 2022, 68, 664-672.	1.4	4
231	Neuropsychological Functioning in Users of Serotonergic Psychedelics â€“ A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 739966.	1.6	4
232	Fetal-Adult Cardiac Transcriptome Analysis in Rats with Contrasting Left Ventricular Mass Reveals New Candidates for Cardiac Hypertrophy. PLoS ONE, 2015, 10, e0116807.	1.1	4
233	Falls Self-Efficacy in German Nursing Home Residents: Assessment of Validity and Determination of a Cutoff Point. Research in Gerontological Nursing, 2016, 9, 134-144.	0.2	4
234	Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. Observational registry. Kardiologia Polska, 2021, 79, 1265-1267.	0.3	4

#	Article	IF	Citations
235	Mapping and confirmation of a major left ventricular mass QTL on rat chromosome 1 by contrasting SHRSP and F344 rats. Physiological Genomics, 2013, 45, 827-833.	1.0	3
236	Development of progressive albuminuria in male Munich Wistar FrÃ¶mter rats is androgen dependent. Physiological Genomics, 2015, 47, 281-289.	1.0	3
237	Evaluation einer Fortbildung fÃ¼r Pflegende zum Schmerzmanagement in Pflegeheimen. HeilberufeSCIENCE, 2016, 7, 9-18.	0.7	3
238	Immobilization and high platelet count are associated with thromboembolic complications in heparin-induced thrombocytopenia. Pharmacoepidemiology and Drug Safety, 2017, 26, 1149-1155.	0.9	3
239	The Impact of Measurement Methods on Office Blood Pressure and Management of Hypertension in General Practice. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 483-491.	1.0	3
240	Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virusâ€“Positive Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2019, 41, 53-58.	1.0	3
241	Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis. European Journal of Internal Medicine, 2019, 61, 29-33.	1.0	3
242	Hypertension management during the COVID-19 pandemic: what can we learn for the future?. Blood Pressure, 2022, 31, 47-49.	0.7	3
243	Genetic low nephron number hypertension is associated with altered expression of osteopontin and CD44 during nephrogenesis*. Journal of Perinatal Medicine, 2013, 41, 295-299.	0.6	2
244	Dialysis-Associated Hypertension Treated with Telmisartan â€“ DiaTel: A Pilot, Placebo-Controlled, Cross-Over, Randomized Trial. PLoS ONE, 2013, 8, e79322.	1.1	2
245	Genetic Variants on Rat Chromosome 8 Exhibit Profound Effects on Hypertension Severity and Survival During Nitric Oxide Inhibition in Spontaneously Hypertensive Rats. American Journal of Hypertension, 2014, 27, 294-298.	1.0	2
246	Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2014. Clinical Research in Cardiology, 2014, 103, 591-597.	1.5	2
247	Novel candidate genes for impaired nephron development in a rat model with inherited nephron deficit and albuminuria. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 1051-1058.	0.9	2
248	Genetic low nephron number hypertension is associated with altered expression of key components of the renin-angiotensin system during nephrogenesis. Journal of Perinatal Medicine, 2016, 44, 705-9.	0.6	2
249	Pain-coping types among older community-dwelling care receivers with chronic pain. Aging and Mental Health, 2022, 26, 1417-1425.	1.5	2
250	Xalia, a Non-Interventional Study Comparing Rivaroxaban with Standard Anticoagulation for Initial and Long-Term Therapy in Deep Vein Thrombosis. Blood, 2015, 126, 894-894.	0.6	2
251	Subgroup Analysis of Patients with Cancer in Xalia - a Non-Interventional Study of Rivaroxaban in Routine Treatment of Deep Vein Thrombosis. Blood, 2016, 128, 1438-1438.	0.6	2
252	Attended vs. unattended blood pressure â€“ learnings beyond SPRINT. Blood Pressure, 2021, 30, 1-3.	0.7	2

#	Article	IF	Citations
253	Antihypertensive Drugs. , 2021, , 165-174.		2
254	MiRNA-29b and miRNA-497 Modulate the Expression of Carboxypeptidase X Member 2, a Candidate Gene Associated with Left Ventricular Hypertrophy. International Journal of Molecular Sciences, 2022, 23, 2263.	1.8	2
255	Hypertension in older patients: a STEP forward?. Blood Pressure, 2022, 31, 118-120.	0.7	2
256	Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial. Hypertension, 2022, 79, 1856-1865.	1.3	2
257	Cell biology in hypertension. Current Opinion in Cardiology, 1991, 6, 680-685.	0.8	1
258	Real life studies and good clinical practice â€“ Authors' reply. Lancet Haematology,the, 2016, 3, e160-e161.	2.2	1
259	TMEM63C, a Potential Novel Target for Albuminuria Development, Is Regulated by MicroRNA-564 and Transforming Growth Factor beta in Human Renal Cells. Kidney and Blood Pressure Research, 2020, 45, 850-862.	0.9	1
260	Hypertension Research Quo Vadis?. Hypertension, 2020, 76, 1423-1424.	1.3	1
261	Why we do not need a single independent international hypertension clinical practice guideline. Journal of Hypertension, 2021, 39, 2125-2127.	0.3	1
262	Effect of a common UMOD variant on kidney function, blood pressure, cognitive and physical function in a community-based cohort of older adults. Journal of Human Hypertension, 2022, 36, 983-988.	1.0	1
263	Blood Pressure Control. , 2021, , 317-322.		1
264	Mild chronic hypertension in pregnancy: to treat or wait?. Blood Pressure, 2022, 31, 121-124.	0.7	1
265	Isolation of Renal Glomeruli Specific Cell Material Using an Experimental NIR-Laser Microdissection Setup. Medical Laser Application: International Journal for Laser Treatment and Research, 2002, 17, 21-24.	0.4	0
266	Impact of socio-economic factors on the long-term effectiveness of antihypertensive treatment with an angiotensin II receptor blocker: an observational study. Current Medical Research and Opinion, 2014, 30, 1947-1955.	0.9	0
267	ESH Annual Meeting 2018. European Heart Journal, 2018, 39, 3836-3839.	1.0	0
268	FO029HYPERTENSION CONTROL AND MORTALITY IN A COHORT OF OLDER ADULTS. Nephrology Dialysis Transplantation, 2018, 33, i30-i31.	0.4	0
269	Pain-Associated Clusters Among Nursing Home Residents and Older Adults Receiving Home Care in Germany. Journal of Pain and Symptom Management, 2020, 60, 48-59.	0.6	0
270	MO431LIPIDOMIC ANALYSIS IN A NON-DIABETIC RAT MODEL WITH HYPERFILTRATION AND ALBUMINURIA REVEALS DYNAMIC CHANGES IN THE PROSTAGLANDIN E2 PATHWAY DURING ONSET OF ALBUMINURIA AS A POTENTIAL CAUSATIVE MECHANISM. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0

#	Article	IF	Citations
271	Molekular definierte Modelle in der Herz-Kreislauf-Forschung. , 1998, , 401-412.		0
272	Novel Drugs in the Treatment of Hypertension. Updates in Hypertension and Cardiovascular Protection, 2016, , 157-178.	0.1	0
273	Blood Pressure Control. , 2020, , 1-6.		0
274	Reply. Journal of Hypertension, 2022, 40, 624-626.	0.3	0
275	Prescribing blood pressure lowering drugs irrespective of blood pressure?. Journal of Hypertension, 2022, 40, 1050-1051.	0.3	0
276	Thirty years with LIFEâ€"a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy. Blood Pressure, 2022, 31, 125-128.	0.7	0